Stay updated on SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial page.

Latest updates to the SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedUpdated the page revision from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedRevision: v3.4.2 was added. The funding-status notice and Revision: v3.4.1 were removed.SummaryDifference0.4%

- Check43 days agoChange DetectedA government funding lapse notice is now displayed on the page, and the site revision tag has been updated to v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check50 days agoChange DetectedGlossary visibility was added and QC-related labels were updated to show the new revision (v3.4.0), replacing the previous version and capitalization variants.SummaryDifference0.2%

- Check64 days agoChange DetectedRevision: v3.3.4 replaces the previous v3.3.3 on the page; no substantive changes to study details or eligibility criteria are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check86 days agoChange DetectedA dedicated Locations section has been added listing sites by state (Arizona, Maryland, Oregon, Texas). The previous state-specific subsections were removed, indicating a reorganization of site listings.SummaryDifference0.5%

Stay in the know with updates to SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial page.